Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX).

Full DD Report for FOMX

You must become a subscriber to view this report.


Recent News from (NASDAQ: FOMX)

Foamix Pharmaceuticals' (FOMX) CEO Dave Domzalski on Q1 2018 Results - Earnings Call Transcript
Foamix Pharmaceuticals Ltd. (FOMX) Q1 2018 Earnings Conference Call May 9, 2018 8:30 AM ET Executives Michael Wood – Investor Relations Dave Domzalski – Chief Executive Officer Ilan Hadar – Chief Financial Officer Analysts Bill Maughan – Cowen &a...
Source: SeekingAlpha
Date: May, 09 2018 14:33
Foamix Pharmaceuticals misses by $0.24, misses on revenue
Foamix Pharmaceuticals (NASDAQ: FOMX ): Q1 EPS of -$0.69 misses by $0.24 . More news on: Foamix Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, , Read more ...
Source: SeekingAlpha
Date: May, 08 2018 17:11
Foamix Reports First Quarter 2018 Financial Results and Provides Corporate Update
REHOVOT, Israel, May 08, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs i...
Source: GlobeNewswire
Date: May, 08 2018 17:04
Foamix Announces Dosing of Last Patient in Third Phase 3 Acne Study for Minocycline Foam FMX101
Top-line Results Expected in the Third Quarter of 2018 REHOVOT, Israel, and BRIDGEWATER, N.J., May 07, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foam...
Source: GlobeNewswire
Date: May, 07 2018 08:00
Foamix Pharmaceuticals First Quarter Financial Results Conference Call & Webcast Scheduled for May 9
REHOVOT, Israel, and BRIDGEWATER, N.J., April 24, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in der...
Source: GlobeNewswire
Date: April, 24 2018 08:00
Foamix Announces $16 Million Investment by OrbiMed
REHOVOT, Israel and BRIDGEWATER, N.J., April 16, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in derm...
Source: GlobeNewswire
Date: April, 16 2018 08:00
Paratek: A Review Of Progress And Preview Of 2018
Paratek Pharmaceuticals ( PRTK ) is a biopharmaceutical company making steady progress towards approval of its novel tetracycline antibiotic, omadacycline. Omadacycline produced impressive results in three phase 3 studies, the results of which, coupled with other progress, can no longer be see...
Source: SeekingAlpha
Date: March, 21 2018 15:56
Foamix Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2018
REHOVOT, Israel, and BRIDGEWATER, N.J., March 08, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in der...
Source: GlobeNewswire
Date: March, 08 2018 08:00
Foamix Pharmaceuticals to Present at the Cowen & Company 38th Annual Health Care Conference
REHOVOT, Israel, and BRIDGEWATER, N.J., March 06, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in der...
Source: GlobeNewswire
Date: March, 06 2018 08:00
Dermira Tumbles On Phase 3 Data For Acne, But Hope Remains
On Monday, Dermira ( DERM ) announced that it had failed two phase 3 trials using its topical gel olumacostat glasaretil ((DRM01)). Both of these trials were treating patients with acne. It is really bad that the company did not succeed in either study, but that doesn't mean that it is the e...
Source: SeekingAlpha
Date: March, 06 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-175.305.355.435.2538,927
2017-02-029.9110.0110.189.85137,520
2017-02-0110.0810.0110.229.85141,168
2017-01-319.6510.0610.129.5897,305
2017-01-309.859.719.899.7058,529

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-05-252,20231,6966.9472Cover
2018-05-2446,57469,47767.0351Short
2018-05-2311,70479,31514.7564Cover
2018-05-225,75729,80319.3168Cover
2018-05-2121,51849,65743.3333Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on FOMX.


About Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX)

Logo for Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: FOMX)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 14 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 09 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 08 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 07 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 16 2018
      Prospectus filed under Rule 424(b)(5)
      Filing Type: 424B5Filing Source: edgar
      Filing Date: April, 16 2018
      Notice from the SEC of registration effectiveness
      Filing Type: EFFECTFiling Source: edgar
      Filing Date: April, 12 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 11 2018
      Simplified registration form
      Filing Type: S-3Filing Source: edgar
      Filing Date: April, 02 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: March, 29 2018

       

       


      Daily Technical Chart for (NASDAQ: FOMX)

      Daily Technical Chart for (NASDAQ: FOMX)


      Stay tuned for daily updates and more on (NASDAQ: FOMX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: FOMX)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      The Subway Trader
      @TheSubwayTrader

       

       


      Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in FOMX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of FOMX and does not buy, sell, or trade any shares of FOMX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/